Future of theranostics: An outlook on precision oncology in nuclear medicine

Keyphrases

• Nuclear Medicine 100%
• Lutetium-177 (177Lu) 100%
• Theranostics 100%
• Precision Oncology 100%
• Fibroblast Activation Protein Inhibitor 75%
• Malignancy 50%
• Radiopharmaceuticals 50%
• Iodine-131 (131I) 50%
• Therapeutic Use 25%
• Clinical Investigation 25%
• Rapid Development 25%
• Tumor 25%
• New Targets 25%
• PET Imaging 25%
• Prostate-specific Antigen 25%
• Oncology 25%
• Personalized Medicine 25%
• Malignant Disease 25%
• B-cell Lymphoma 25%
• Pancreatic Adenocarcinoma 25%
• Carbohydrate Antigen 19-9 (CA19-9) 25%
• Zirconium-89 (89Zr) 25%
• Advanced Tumor 25%
• Ligand-receptor Binding 25%
• Neuroendocrine Neoplasms 25%
• Neuroblastoma Cells 25%
• Low-side 25%
• Molecular Alterations 25%
• Neurotensin Receptor 25%
• Advanced Prostate Cancer 25%
• Clinical Status 25%
• Gallium-68 25%
• Endoradiotherapy 25%
• B7-H3 25%
• Radiolabeled Antibody 25%
• Radionuclide Therapy 25%
• Fibroblast Activation Protein 25%
• CD37 25%
• Differentiated Thyroid Cancer 25%
• Omburtamab 25%
• Labeled Antibody 25%
• Somatostatin Analogs 25%

Medicine and Dentistry

• Lutetium 177 100%
• Fibroblast 100%
• Nuclear Medicine 100%
• Precision Oncology 100%
• Protein Inhibitor 75%
• Neoplasm 50%
• Cancer 50%
• Iodine 131 50%
• Radiopharmaceutical 50%
• Positron Emission Tomography 25%
• Side Effect 25%
• Personalized Medicine 25%
• Prostate Cancer 25%
• Prostate Specific Membrane Antigen 25%
• Oncology 25%
• Gallium 68 25%
• Indium 111 25%
• Pancreas Adenocarcinoma 25%
• B-Cell Lymphoma 25%
• Upregulation 25%
• Zirconium 89 25%
• Neuroblastoma Cell 25%
• CA19-9 25%
• Neuroendocrine Tumor 25%
• Neurotensin Receptor 25%
• Somatostatin Derivative 25%
• Radionuclide Therapy 25%
• Yttrium 90 25%
• Differentiated Thyroid Cancer 25%
• Omburtamab 25%
• Lilotomab 25%
• Diseases 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Lutetium 177 100%
• Protein Inhibitor 75%
• Iodine-131 50%
• Neoplasm 50%
• Radioisotope 25%
• Lilotomab 25%
• Side Effect 25%
• Pancreas Adenocarcinoma 25%
• Prostate Cancer 25%
• Prostate Specific Membrane Antigen 25%
• Neurotensin Receptor 25%
• Zirconium 89 25%
• Neuroendocrine Tumor 25%
• Neuroblastoma 25%
• Somatostatin Derivative 25%
• Indium 111 25%
• B Cell Lymphoma 25%
• Gallium 68 25%
• Yttrium 90 25%
• Differentiated Thyroid Cancer 25%
• Omburtamab 25%
• Polyethylene Terephthalate 25%
• Diseases 25%